BR112013028407A2 - "sequências de aminoácido direcionadas em relação aos polipeptídeos de il-17a, il-17f e/ou il17-a/f compreendendo as mesmas, seus usos, polipeptídeos, e composição farmacêutica". - Google Patents

"sequências de aminoácido direcionadas em relação aos polipeptídeos de il-17a, il-17f e/ou il17-a/f compreendendo as mesmas, seus usos, polipeptídeos, e composição farmacêutica".

Info

Publication number
BR112013028407A2
BR112013028407A2 BR112013028407A BR112013028407A BR112013028407A2 BR 112013028407 A2 BR112013028407 A2 BR 112013028407A2 BR 112013028407 A BR112013028407 A BR 112013028407A BR 112013028407 A BR112013028407 A BR 112013028407A BR 112013028407 A2 BR112013028407 A2 BR 112013028407A2
Authority
BR
Brazil
Prior art keywords
polypeptides
amino acid
acid sequences
pharmaceutical composition
sequences directed
Prior art date
Application number
BR112013028407A
Other languages
English (en)
Other versions
BR112013028407B1 (pt
Inventor
Alain Vicari
Amanda E I Proudfoot
Ann Union
Denis Bruniquel
Heidi Rommelaere
Joost Alexander Kolkman
Laurent Chevalet
Michael John Scott Saunders
Olivier Leger
Yolande Chvatchko
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013028407(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112013028407A2 publication Critical patent/BR112013028407A2/pt
Publication of BR112013028407B1 publication Critical patent/BR112013028407B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo patente de invenção: "sequências de aminoácido direcionadas em relação aos polipeptídeos de il-17a, il-17f e/ou il17-a/f compreendendo as mesmas". a presente invenção refere-se às sequências de aminoácido que são direcionadas em relação a (como aqui definido) qualquer um dentre il-17a, il-17f e/ou il-17a/f, inclusive combinações das mesmas, bem como a compostos ou construtos, e em particular proteínas e polipeptídeos que compreendem ou essencialmente consistem em uma ou mais tais sequências de aminoácido (da mesma forma referida aqui como "sequências de aminoácido da invenção", "compostos da invenção", e "polipeptídeos da invenção", respectivamente).
BR112013028407-2A 2011-05-05 2012-05-04 Polipeptídeos compreendendo um domínio variável único da imunoglobulina (isv) de ligação a il-17a, il-17f e/ou il17-a/f seus usos e composição farmacêutica compreendendo os mesmos BR112013028407B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482802P 2011-05-05 2011-05-05
US61/482,802 2011-05-05
PCT/EP2012/058313 WO2012156219A1 (en) 2011-05-05 2012-05-04 Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same

Publications (2)

Publication Number Publication Date
BR112013028407A2 true BR112013028407A2 (pt) 2016-11-29
BR112013028407B1 BR112013028407B1 (pt) 2021-11-23

Family

ID=46245559

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028407-2A BR112013028407B1 (pt) 2011-05-05 2012-05-04 Polipeptídeos compreendendo um domínio variável único da imunoglobulina (isv) de ligação a il-17a, il-17f e/ou il17-a/f seus usos e composição farmacêutica compreendendo os mesmos

Country Status (24)

Country Link
US (4) US10017568B2 (pt)
EP (3) EP4105231A1 (pt)
JP (5) JP6628965B2 (pt)
KR (1) KR102083230B1 (pt)
CN (2) CN107098971B (pt)
AU (1) AU2012257942B8 (pt)
BR (1) BR112013028407B1 (pt)
CA (1) CA2834907C (pt)
CL (1) CL2013003090A1 (pt)
DK (1) DK2705058T3 (pt)
EA (1) EA035973B9 (pt)
ES (1) ES2662371T3 (pt)
HR (1) HRP20180380T1 (pt)
HU (1) HUE037225T2 (pt)
IL (1) IL228813B (pt)
LT (1) LT2705058T (pt)
MX (1) MX2013012844A (pt)
MY (1) MY167231A (pt)
NZ (1) NZ616761A (pt)
PT (1) PT2705058T (pt)
SG (2) SG194632A1 (pt)
SI (1) SI2705058T1 (pt)
UA (1) UA117218C2 (pt)
WO (1) WO2012156219A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2014076321A1 (en) * 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
KR20160124165A (ko) 2014-02-21 2016-10-26 제넨테크, 인크. 항-il-13/il-17 이중특이적 항체 및 그의 용도
MX2016014926A (es) 2014-05-16 2017-05-09 Ablynx Nv Dominios variables de inmunoglobulina mejorados.
EP3145945B1 (en) 2014-05-22 2020-07-15 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
GB201500463D0 (en) * 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
AU2016209247B2 (en) 2015-01-21 2021-02-25 Inhibrx Biosciences, Inc. Non-immunogenic single domain antibodies
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
CN116059350A (zh) 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
JP6995127B2 (ja) 2017-02-10 2022-02-04 ジェネンテック， インコーポレイテッド 抗トリプターゼ抗体、その組成物、及びその使用
CN108359011B (zh) * 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN107857818A (zh) * 2017-08-07 2018-03-30 上海科新生物技术股份有限公司 一种针对IL‑17和TNF‑α的双特异性融合蛋白
CN113603776B (zh) * 2018-02-12 2022-10-21 原启生物科技(上海)有限责任公司 Il17抗体及其应用
CN110003329B (zh) * 2019-04-12 2022-09-27 深圳普瑞金生物药业股份有限公司 多肽、il17a/f单域抗体、核苷酸序列及试剂盒
CN113603765B (zh) * 2020-07-15 2024-05-14 百奥赛图(北京)医药科技股份有限公司 Il17f基因人源化的非人动物及其构建方法和应用
WO2022040506A2 (en) * 2020-08-21 2022-02-24 Yale University Nanobody compositions and methods of use of the same
WO2023035272A1 (zh) * 2021-09-13 2023-03-16 深圳华普药物研发有限公司 一种il17抗体及其制备方法和应用
CN117106083A (zh) * 2022-03-25 2023-11-24 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
WO2023203549A1 (en) 2022-04-22 2023-10-26 Moonlake Immunotherapeutics Ag Methods of achieving safe and sustained control of il-17-dependent conditions in subjects responsive to treatment with an anti-il 17a/f nanobody
CN115093483A (zh) * 2022-06-17 2022-09-23 国药中生生物技术研究院有限公司 Il-17ra融合蛋白、药物组合物、注射剂及其应用
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
EP4393948A1 (en) 2022-12-28 2024-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
CN116769027B (zh) * 2023-06-09 2023-12-01 康元医疗科技(大连)有限公司 一种抗il-17纳米抗体、多肽及其应用
CN117843776B (zh) * 2023-12-21 2024-08-30 北京贝来药业有限公司 抗体分子、核酸、制药用途及炎性疾病治疗方法
CN117843804B (zh) * 2023-12-29 2024-08-20 北京贝来药业有限公司 单域抗体串联分子及其序列、产品、制备和应用
CN117843801B (zh) * 2023-12-29 2024-08-02 北京贝来药业有限公司 以白介素家族成员为靶点的新型抗体以及下游产品
CN117820481A (zh) * 2023-12-29 2024-04-05 北京贝来药业有限公司 新型抗体分子及其制药用途
CN117843805B (zh) * 2023-12-29 2024-09-06 北京贝来药业有限公司 抗体分子、核酸分子、药物组合物以及应用
CN118206654B (zh) * 2024-03-05 2024-09-20 北京贝来药业有限公司 用于疾病治疗的新型抗体及其产品和应用
CN117866903B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 单域抗体修饰的干细胞及其在疾病治疗中用途
CN117866905B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基于纳米抗体基因修饰的干细胞及其制备方法和产品
CN117860786B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
EP0640130B1 (en) 1992-05-08 1998-04-15 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
CA2137558A1 (en) 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
ATE198490T1 (de) 1993-06-09 2001-01-15 Unilever Nv Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
DK0839196T3 (da) 1995-07-19 2005-09-12 Inst Genetics Llc Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
WO1998022141A2 (en) 1996-11-19 1998-05-28 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US20020177188A1 (en) 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
EP1469883A2 (en) 1998-02-19 2004-10-27 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
US6486303B1 (en) 1998-04-14 2002-11-26 University Of Medicine & Dentistry Of New Jersey Method for making hormone heterodimers
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
ES2458349T3 (es) 1999-12-23 2014-05-05 Genentech, Inc. Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002242142A1 (en) 2001-02-09 2002-08-28 Johns Hopkins University A cytokine related structurally to il-17
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1578842B1 (en) 2002-12-31 2009-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
MXPA06000347A (es) 2003-07-08 2006-03-28 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
US20060263353A1 (en) 2003-08-20 2006-11-23 Lawson Alastair D G Methods for obtaining antibodies
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
US7882839B2 (en) 2004-06-25 2011-02-08 Ambis Jr Edward J Custom mouthguard
JP2008512987A (ja) 2004-07-22 2008-05-01 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子
CN100396019C (zh) 2004-07-31 2008-06-18 华为技术有限公司 移动终端数据源模拟方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
MY142617A (en) 2004-12-23 2010-12-15 Domantis Ltd Dual specific ligands with increased serum half-life
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2322553A3 (en) 2005-02-14 2011-11-16 Wyeth LLC Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
US7807162B2 (en) 2005-05-20 2010-10-05 Ablynx N.V. Single domain VHH antibodies against von Willebrand factor
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
CA2624781A1 (en) 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies tm and polypeptides against egfr and igf-ir
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
CA2649009A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. Dp-78-like nanobodies
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
EP2040995A1 (en) 2006-06-26 2009-04-01 Aida Centre, S.L. Blister package integrating rfid based tags
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
EP2086998B1 (en) 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
AU2008287195A1 (en) 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2238156B1 (en) 2008-01-29 2014-10-01 Ablynx N.V. Methods to stabilize proteins and polypeptides
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US20090317400A1 (en) * 2008-05-05 2009-12-24 Krzysztof Masternak Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
WO2010034443A1 (en) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof
BRPI1013688A8 (pt) 2009-03-05 2017-02-14 Abbott Lab Proteínas de ligação de il-17.
PL2424889T3 (pl) 2009-04-30 2016-01-29 Ablynx Nv Sposób wytwarzania przeciwciał domenowych
MX2011011729A (es) 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
CN102905727B (zh) 2009-10-30 2016-12-07 詹森生物科技公司 Il-17a拮抗剂
HUE046670T2 (hu) 2010-01-15 2020-03-30 Kirin Amgen Inc Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére
US8965476B2 (en) * 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
ES2660770T3 (es) 2010-10-08 2018-03-26 Novartis Ag Métodos para el tratamiento de psoriasis usando antagonistas de IL-17
KR20180019247A (ko) 2010-11-05 2018-02-23 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
LT2663577T (lt) 2011-01-14 2017-07-25 Ucb Biopharma Sprl Antikūnas, surišantis il-17a ir il-17f
TWI439451B (zh) 2011-03-24 2014-06-01 Hoffmann La Roche 雜環胺衍生物
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CA2853114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
JP6007310B2 (ja) 2012-04-05 2016-10-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトｔｗｅａｋ及びヒトｉｌ１７に対する二重特異性抗体並びにその使用
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
CU24300B1 (es) 2013-02-08 2017-12-08 Novartis Ag Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios
CL2015001213A1 (es) 2015-05-07 2015-07-10 Pontificia Universidad Católica De Chile Método ex vivo para predecir respuesta a un tratamiento inmunomodulador en pacientes con enfermedad inflamatoria, el cual comprende la cuantificación de las razones entre las concentraciones de citoquinas seleccionadas de ifn-gamma/il-17f, il17f/il-10, il-17f/ifn-gamma e il-10/il17f; y kit para llevar a cabo el método.

Also Published As

Publication number Publication date
IL228813A0 (en) 2013-12-31
CA2834907A1 (en) 2012-11-22
NZ616761A (en) 2016-01-29
EP2705058B1 (en) 2018-01-10
MY167231A (en) 2018-08-14
MX2013012844A (es) 2013-11-20
CA2834907C (en) 2023-03-07
CN107098971A (zh) 2017-08-29
JP6768027B2 (ja) 2020-10-14
CN103717618B (zh) 2016-12-07
EA035973B9 (en) 2021-03-30
SG194632A1 (en) 2013-12-30
US10829552B2 (en) 2020-11-10
US20190100584A1 (en) 2019-04-04
SG10201606409TA (en) 2016-09-29
US11773159B2 (en) 2023-10-03
BR112013028407B1 (pt) 2021-11-23
AU2012257942A2 (en) 2014-06-05
AU2012257942B8 (en) 2015-09-17
WO2012156219A9 (en) 2013-04-18
AU2012257942A1 (en) 2013-05-02
JP6628965B2 (ja) 2020-01-15
ES2662371T3 (es) 2018-04-06
KR102083230B1 (ko) 2020-03-02
JP2014516945A (ja) 2014-07-17
AU2012257942A8 (en) 2015-09-10
PT2705058T (pt) 2018-03-20
US20210130452A1 (en) 2021-05-06
DK2705058T3 (en) 2018-03-05
EP4105231A1 (en) 2022-12-21
HUE037225T2 (hu) 2018-08-28
EP2705058A1 (en) 2014-03-12
HRP20180380T1 (hr) 2018-04-06
IL228813B (en) 2018-07-31
EA201391632A1 (ru) 2014-07-30
JP7093380B2 (ja) 2022-06-29
US20140314743A1 (en) 2014-10-23
US10017568B2 (en) 2018-07-10
EA035973B1 (ru) 2020-09-08
JP2024122989A (ja) 2024-09-10
UA117218C2 (uk) 2018-07-10
CN107098971B (zh) 2020-07-10
LT2705058T (lt) 2018-04-10
JP2018154628A (ja) 2018-10-04
CL2013003090A1 (es) 2014-10-10
SI2705058T1 (en) 2018-04-30
US20220195031A1 (en) 2022-06-23
CN103717618A (zh) 2014-04-09
EP3363815A1 (en) 2018-08-22
WO2012156219A1 (en) 2012-11-22
JP2022137058A (ja) 2022-09-21
AU2012257942B2 (en) 2015-08-20
JP2020193195A (ja) 2020-12-03
KR20140132661A (ko) 2014-11-18

Similar Documents

Publication Publication Date Title
BR112013028407A2 (pt) "sequências de aminoácido direcionadas em relação aos polipeptídeos de il-17a, il-17f e/ou il17-a/f compreendendo as mesmas, seus usos, polipeptídeos, e composição farmacêutica".
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
BRPI0923346A2 (pt) Proteinas em super-helice antiparalela de cadeia simples
MX2021010668A (es) Proteinas de fusion de citoquinas.
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
CY1116100T1 (el) Παραγωγα πυριμιδινονης, η παρασκευη τους και η φαρμακευτικη τους χρηση
BR112015006426A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos
BR112017019401A2 (pt) método de purificação de proteínas de fusão de albumina
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112013009083A8 (pt) anticorpos humanos de oncostatin m e métodos de uso
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2012, OBSERVADAS AS CONDICOES LEGAIS.